Emerging tumor-agnostic molecular targets Review
| Authors: | Bhamidipati, D.; Schram, A. M. |
| Review Title: | Emerging tumor-agnostic molecular targets |
| Abstract: | Advances in tumor molecular profiling have uncovered shared genomic and proteomic alterations across tumor types that can be exploited therapeutically. A biomarker-driven, disease-agnostic approach to oncology drug development can maximize the reach of novel therapeutics. To date, eight drug–biomarker pairs have been approved for the treatment of patients with advanced solid tumors with specific molecular profiles. Emerging biomarkers with the potential for clinical actionability across tumor types include gene fusions involving NRG1, FGFR1/2/3, BRAF, and ALK and mutations in TP53 Y220C, KRAS G12C, FGFR2/3, and BRAF non-V600 (class II). We explore the growing evidence for clinical actionability of these biomarkers in patients with advanced solid tumors. ©2024 American Association for Cancer Research. |
| Keywords: | human tissue; genetics; mutation; review; solid tumor; antineoplastic agents; antineoplastic agent; neoplasm; neoplasms; biological marker; fibroblast growth factor receptor 3; tumor marker; gene fusion; phase 3 clinical trial; drug therapy; therapy; fibroblast growth factor receptor 1; fibroblast growth factor receptor 2; molecularly targeted therapy; molecular targeted therapy; procedures; humans; human; female; biomarkers, tumor; agnostic; molecular fingerprinting |
| Journal Title: | Molecular Cancer Therapeutics |
| Volume: | 23 |
| Issue: | 11 |
| ISSN: | 1535-7163 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2024-11-01 |
| Start Page: | 1544 |
| End Page: | 1554 |
| Language: | English |
| DOI: | 10.1158/1535-7163.Mct-23-0725 |
| PUBMED: | 39279103 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF. Corresponding MSK author is Alison M. Schram -- Source: Scopus |
